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Opioid Analgesia
in Horses
R. Eddie Clutton, BVSc, MRCVS, DVA, MRCA
Opioid analgesics have been the foundation of human pain management for centuries,
and their value in animals has increased since Yoxall1 proposed that it was the veter-
inarian’s duty to alleviate pain whenever it may occur. Compared with other domesti-
cated species, the horse has benefitted less from the increased understanding of
opioid pharmacology in animals. This situation has occurred because early literature
was overlooked, whereas later work, which examined adverse side effects rather
than analgesia, concluded that analgesic and excitatory doses were irreconcilably
close. More recent studies have indicated a widening role for opioid analgesics in
equine pain management, and radioligand studies have revealed a basis for the equine
response pattern to opioid analgesics.2
MORPHINE AND OPIOID ANALGESICS: EXCITATORY EFFECTS
The excitatory effects of morphine (fear of which is an important factor limiting the
veterinary use of opioid drugs in horses3) were first described in 1899.4 In 1917 Milks5
reported that 2 to 5 grains of morphine provided “maximal analgesia with a minimum
of excitement.” Fro¨hner6 reported that excitement combined with sensory and motor
depression characterized all cases when morphine doses of 0.4, 0.75, 1.5, and 10 g
were given to horses. These early reports omitted body mass data for the animals
described, but an assumption that test animals weighed 600 kg indicates the doses
studied were considerably greater than those used in contemporary practice. Amadon
and Craigie7 described minimal analgesic and excitant morphine doses of 0.2 and 0.5
mg/kg, respectively in pain-free horses, and ensured that veterinary scientists there-
after focused on the excitatory and locomotor side effects of the drug rather than its
analgesic properties. To complicate matters, the term excitation when applied to
opioid-induced side effects in horses was subsequently used indiscriminately. For
example, in one study, excitation involved “continuous head nodding, digging, shifting
of limbs, vocalizing, trotting and even galloping”,8 whereas in another the signs of
excitement included muzzle tremors, muscle twitching, head jerks, head pressing,
and a raised tail.9
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Morphine, meperidine, pentazocine, methadone, and hydromorphone were studied
in varying numbers1–9 of pain-free horses in what has probably become the most cited
reference on opioid-induced locomotion in horses.10 The study revealed 3 important
points: (1) that opioids induce eating behavior at low doses and dose-dependent loco-
motor activity with incoordination at high doses; (2) that there is marked individual vari-
ation in responses; and (3) that the median effective value for morphine for increasing
locomotion in pain-free animals is 0.91 mg/kg. This dose is considerably greater than
the doses used to produce analgesia.
The opioid antagonist naloxone (15 mg/kg) entirely prevented locomotor responses
to the m-agonist fentanyl in pain-free horses, whereas a higher dose (20 mg/kg)
reduced those of morphine by 75%.11 This finding indicates that opioid-induced loco-
motion is mediated via opioid receptors. The propensity of an opioid analgesic to
promote locomotion may be greater with m- compared with k-agonists.12 although
k-agonism more commonly causes ataxia and staggering.13,14 However, the evidence
is confusing. The k-agonist butorphanol (50 mg/kg intravenously [IV]) increased loco-
motion compared with fentanyl (5 mg/kg), although given later in the same animals,
fentanyl antagonized the locomotor effect of butorphanol.15 In contrast, another study
showed that the k-agonist U50,488H increased the intensity of fentanyl-induced loco-
motion.16 Although the role of opioid receptor subtypes involved in drug-induced loco-
motion remains unclear, much evidence points to the role of dopamine because
dopamine antagonists reduce the locomotor response in most species studied. Ace-
promazine has antidopaminergic effects and 0.16 mg/kg IV partly blocked the loco-
motor effects of fentanyl (20 mg/kg) and morphine (2.4 mg/kg) in horses.11 In
another study, acepromazine (0.1 mg/kg) injected IV before etorphine gave better
relaxation than xylazine 3.0 mg/kg intramuscularly (IM).17 However, the participation
of dopamine is not straightforward: the dopamine antagonists NNC 01-0756 and eti-
clopride not only failed to inhibit alfentanil-induced locomotion after 20 mg/kg IV, but
appeared to stimulate locomotion in their own right.18
Wide dose ranges tested in small study groups make it difficult to determine
whether different receptors mediate different types of excitatory behaviors. However,
k-agonism might be associated with yawning, because this was seen with butorpha-
nol (50 mg/kg IV)15 and U50,488H (30, 60, and 120 mg/kg).16 A sample of the range of
side effects produced by high-dose opioid analgesics in pain-free horses is summa-
rized in Table 1. This table illustrates a wide variation in response to fixed drug doses
between studies, which in turn reflects the variation observed between horses within
the same study.10 Analysis of individual studies further reveals that a given animal
frequently reacted differently in response to the same drug given under identical
conditions. In one study of buprenorphine26 3 mg/kg caused signs of severe excitation,
whereas doses of 5 and 10 mg/kg IV given later produced only hallucinations. Although
this might reflect a true dose effect, it raises the question whether some horses and
ponies used extensively in opioid research became opioid dependent and/or tolerant,
despite reported washout periods between trials.
DO OPIOID DRUGS PRODUCE ANALGESIA IN HORSES?
The use of opioid analgesics in horses can be justified when the benefits of their anal-
gesic and sedative properties outweigh the disadvantages of potential side effects.
However, demonstrating the analgesic properties of opioid analgesics is not straight-
forward (at least under experimental conditions) because of inconsistent results.12
This finding may indicate biologic variability amongst the animals studied, inconsistent
drug effects, or the use of flawed pain models.
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Opioid Analgesia: Experimental Studies
Most experimental studies on the analgesic properties of opioid analgesics in horses
have tested: (1) superficial analgesia by focusing a radiant light source onto the black
painted skin overlying the distal limb or withers; the increasing time taken for the
animal to respond by lifting the limb or twitching the skin in response to local heating
(the withdrawal reflex latency) is taken to indicate an increasing level of analgesia; (2)
visceral analgesia, using accelerometry to detect an animal’s reaction to the
increasing pressure in a rubber balloon implanted in the cecum; and (3) deep pain,
by heating of an element implanted in the lateral surface of the humerus and recording
the withdrawal reflex latency.28 An alternative method (dental dolorimetry) involves
recording the minimum electrical current applied to the canine tooth pulp nerve that
elicits a head-lift or jaw-opening response.29
One or more of these techniques in combination have been used to show and/or
compare the analgesic effects of the k-agonist U50,488H,30 fentanyl (0.22 mg/kg),
meperidine (4.4 mg/kg), methadone (0.22 mg/kg), oxymorphone (0.033 mg/kg),
pentazocine (2.2 mg/kg), xylazine (2.2 mg/kg),28 butorphanol (0.22 mg/kg), flunixin
(2.2 mg/kg), levorphanol (0.033 mg/kg), morphine (0.66 mg/kg), xylazine (2.2 mg/
kg),21 butorphanol (0.05, 0.1, 0.2, and 0.4 mg/kg IV), and pentazocine (2.2 mg/kg
IV)31 in small (3–6) groups of horses or ponies. However, the assumption that
increasing withdrawal reflex latencies indicate increasing degrees of analgesia alone
is flawed. First, an animal’s inclination to lift its feet is probably affected by drug-
induced ataxia, if present. Alternatively, opioid-induced stepping behavior may
complicate the interpretation of limb withdrawal.31 Many analgesic studies have incor-
porated a2 agonist drugs (eg, xylazine
21,28 or detomidine32,33) and have concluded
that opioid analgesics provide less analgesia than a2 agonists used alone, or
contribute little analgesia to a2 agonist/opioid combinations. This finding is not
surprising. All 3 tests for analgesia rely on motor responses as the experimental end
point, which is likely to be delayed, if not by the sedative, then by the widely recog-
nized muscle-relaxing properties of a2–agonist drugs. These and other factors may
explain the wide variation in drug effects as well as discrepancies between the anal-
gesic properties of opioids identified under experimental, compared with clinical,
circumstances.30 Furthermore, both heat and electrical current produce phasic pain
of short duration that responds less to analgesics than tonic pain.34 New techniques
using electrophysiologic methods to investigate the pharmacologic modulation of
nociception (eg, the nociceptive withdrawal reflex [NWR] and temporal summation)
have been used in experimental equine pain research.35 The NWR enables the exam-
ination of drug effects on evoked activity in Ab and Ad fibers, whereas temporal
summation provides information on drug-related changes in the gain of the nocicep-
tive system and modulation of central integration mechanisms. These methodologies
may reveal the analgesic potential of opioid analgesics more accurately than previous
methods.36
Opioid Analgesia: Clinical Studies
Discrepancies between experimental and clinical experiences may also be related to
a belief that the risk of adverse opioid-mediated reactions is inversely proportional to
the extent of the recipient’s pain.37 There is a paucity of literature supporting this
subject. In one study, the responses of 66 horses with abdominal pain to butorphanol
(0.1 mg/kg IV) were considered to be excellent (a pronounced analgesic effect was
produced for a period adequate to permit specific therapy) or good (a noticeable
analgesic effect with minor indications of pain).38 In one case report39 sublingual
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Table 1
Behavioral side effects associated with opioid analgesic use in pain-free Equidae
References Dose n Effect
Morphine
19 70 mg/kga Unstated Locomotor stimulation during recovery from
general anesthesia (unsubstantiated)
10 100 mg/kg 5 ponies Sham feeding, drinking and facial grimacing
20 120 mg/kg Unstated Dysphoria, then euphoria
10 0.3 mg/kg 4 horses 1 of 5 showed increased locomotor activityb
0.6 mg/kg 4 horses 4 of 5 showed increased locomotor activity; mean
step rate 5 30 steps per 2 minutes
21 0.66 mg/kg 8 ponies 1 unaffected, 7 were restless
10 1.2 mg/kg 4 horses Mean step rate 5 50 steps per 2 minutes (mean)
Marked propensity to eat from the hay rack; animals
swiped at hay as they passed manger, but unable
to chew or swallow prehended food
2.4 mg/kg Mean step rate 5100 steps per 2 minutes (mean)
Loss of coordination; walked as if oblivious to
surroundings; played with, rather than drank,
offered water; continued to eat large amounts
of hay
Incoordination and collapse
Meperidine
10 1.0 mg/kg 1 horse No effect
2.5 mg/kg Modest increase in locomotor activity
5.0 mg/kg Incoordination, shaking, immobility, then a good
locomotor response
Pentazocine
10 0.25 mg/kg 6 horses Tendency to eat
0.5 mg/kg 6 horses Tendency to eat
1.0 mg/kg 6 horses Hay eating increased, incoordination
2.0 mg/kg 10 horses Severe incoordination, reluctance to walk
Methadone
10 0.1 mg/kg 4 horses Dose-dependent increase in stepping rate
0.5 mg/kg Poor coordination
1.0 mg/kg Tended to go down
Fentanyl
15 5 mg/kg 4 ponies Increased locomotion
11 20 mg/kg 3 horses Increased locomotion
16 20 mg/kg 6 horses Head bobbing, food snatching, cribbing
Alfentanyl
22 4 and 10 mg/kg 6 horses No effect
20 and 40 mg/kg Box walking, bizarre eating behaviors, head tossing,
and shaking
Butorphanol
15 50 mg/kg Yawning
23 0.1–0.13 mg/kg Staggering and ataxia
24 0.1 mg/kg Box walking
25 0.2 mg/kg Apprehension, increased locomotor activity, ataxia
21 0.22 mg/kg Nodding, pacing, pawing, body swinging, head
shaking, shivering
(continued on next page)
Eddie Clutton496
buprenorphine (6 mg/kg) was given twice daily to a filly with traumatic head and neck
injuries and in which signs of pain were unresponsive to phenylbutazone. After admin-
istration, “the filly became sedated and noticeably more comfortable. The neck
muscles relaxed and the filly moved its head and neck more freely. Mild euphoria
was displayed by the filly’s tranquil and affectionate temperament. No signs of excite-
ment of the central nervous system were seen.” This report supports the view that
opioids are beneficial when given to horses with real (ie, nonexperimental) pain.
OPIOID ANALGESICS AND STANDING SURGICAL ANESTHESIA
Do Opioids Enhance the Sedative Effects of a2 Agonists?
It seems so. Morphine (0.1 mg/kg), methadone (0.1 mg/kg), butorphanol (50 mg/kg),
but not meperidine (1.0 mg/kg) improved the sedative effects of intravenous detomi-
dine (10 mg/ kg) in 3 ponies and a thoroughbred and decreased responses to external
stimuli.9 In another study, the inclusion of butorphanol (50 mg/kg, IV) to one of 2 romi-
fidine doses (40 and 80 mg/kg, IV) reduced responses in 4 pain-free ponies and one
thoroughbred when the animals’ coronets were touched, their ears tickled, a cloth
was flapped in front, and hands were clapped behind them. However, the height of
the muzzle from the ground was not lessened by the addition of butorphanol, which
indicates that low-dose romifidine does not measurably relax the cervical muscles.40
When the effects of intravenous detomidine (30 mg/kg), xylazine (1.1 mg/kg), and xyla-
zine (1.1 mg/kg) with morphine (0.75 mg/kg up to 300mg) were compared in 99 horses
undergoing bronchoalveolar lavage, no significant differences between treatments
were found. However, those assessing the level of sedation considered it to be unnec-
essarily deep. Opioids conferred no benefit because all animals were overdosed.41
Do Opioid Analgesics Enhance the Experimentally Determined Analgesic Effects
of a2 Agonists?
Three studies indicate an additive or synergistic effect, although one, using dental
dolorimetry, concluded that xylazine (1.1 mg/kg IV) alone prevented motor responses
to electrocution equal to that induced with xylazine/morphine (0.75 mg/kg IV), xyla-
zine/butorphanol (0.04 mg/kg IV), or xylazine/nalbuphine (0.75 mg/kg IV) combina-
tions.29 In contrast, observers grading analgesia in the face of electrical and
Table 1
(continued)
References Dose n Effect
Buprenorphine
26 3 mg/kg 10 horses Head nodding, pawing, chewing, facial rictus,
a violent and potentially dangerous excitation
crisis
5 and 10 mg/kg Marked ataxia, CN system excitation, or
hallucinations in 3 animals
8 5 and 10 mg/kg 6 horses Continuous head nodding, digging, shifting of
limbs, vocalizing, trotting, galloping
27 10 mg/kg 6 horses Continuous head nodding, head shaking, neighing,
pawing, shifting of ground support, and
restlessness
a All doses intravenous unless otherwise stated.
b A statistically significant increase in the number of steps taken in a 2-minute sampling period.
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pressure stimuli applied to the body wall produced by xylazine (0.66 mg/kg IV)
combined with one of 2 morphine doses (0.12 or 0.66 mg/kg IV) opined that analgesia
was considerably improved when xylazine was combined with the higher morphine
dose.20 Detomidine (10 mg/kg IV) alone, or combined with butorphanol (25 mg/kg) or
levomethadone (100 mg/kg),33 caused a significant temporary increase in the nocicep-
tive threshold (established electrically and pneumatically), although butorphanol and
levomethadone both increased the threshold and prolonged antinociception
compared with detomidine alone. The same results were found in a similar study
examining the same drugs32 but these investigators expressed concern that the stim-
ulus applied (electrical or mechanical) might influence the interpretation of drug
effects, because although both butorphanol and levomethadone increased the reac-
tion threshold to a similar degree, the threshold increase was more apparent when the
coronary band was heated.
Do the Analgesic Properties of Opioids Compare with a2 Agonists?
The contemporary popularity of multimodal pain therapy challenges the need to
compare the analgesic effects of individual a2 agonist and opioid drugs, because
most practitioners now recognize the benefits of using several analgesic drugs in
combination. Nevertheless, one study comparing the effects of xylazine (2.2 mg/
kg IM), pentazocine (1 mg/kg IM), and meperidine (2.2 mg/kg IM) injected 10
minutes after colic signs had been induced by cecal balloon inflation42 concluded
that xylazine was the only drug that provided consistent analgesia. A similar
tendency to attribute the suppression of colic signs to a pure analgesic, rather
than a sedative or muscle-relaxing effect, was apparent in a study comparing butor-
phanol (0.1 mg/kg) with detomidine (20 or 40 mg/kg), intravenous flunixin (1.0 mg/kg)
and xylazine (0.5 mg/kg) in 152 horses presenting with colic.43 Butorphanol was
considered unsatisfactory as an analgesic 90% of the time, whereas detomidine
was considered to be superior.
OPIOID ANALGESICS AND TOTAL INTRAVENOUS ANESTHESIA
The evidence that the beneficial effects of opioids in standing surgical techniques
may extend to those performed under total intravenous anesthesia (TIVA) is not
compelling. Love and colleagues44 studied the effects of preoperative butorphanol
(0.1 mg/kg IV) on postcastration pain in 20 ponies and concluded that a single
preoperative dose does not provide adequate postoperative analgesia for open
castration in colts. In another study of colt castration (n 5 36)45 the analgesic effects
of butorphanol alone (0.05 mg/kg IM before surgery, then every 4 hours for 24
hours), phenylbutazone alone (4.4 mg/kg IV, before surgery and then 2.2 mg/kg
by mouth, every 12 hours for 3 days) or butorphanol and phenylbutazone at the
aforementioned dosages were similar. However, every horse in the study received
preoperative intratesticular lidocaine, which may have obscured differences
between treatments. One study46 compared the effects of butorphanol (50 mg/kg
IV), morphine (0.1 mg/kg IV), or saline given with romifidine (100 mg/kg IV) in 54
ponies undergoing field castration and found sedation was significantly better in
ponies receiving butorphanol compared with saline. Quality of anesthesia was better
in the butorphanol group compared with the morphine and control groups. Quality of
induction and recovery were not significantly different between groups, nor were
recovery time and the number of repeated anesthetic doses required during surgery.
This finding indicates that butorphanol at least improves the quality of some TIVA
anesthetic techniques.
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OPIOID ANALGESICS AND INHALATIONAL ANESTHESIA
The Effects of Opioid Analgesics on Minimum Alveolar Concentration
The sparing effects of morphine (and those of other opioids) on inhalational agents are
less obvious in horses compared with other species.12 The minimum alveolar concen-
tration (MAC) (ie, the end-tidal concentration of inhaled anesthetic preventing
purposeful responses to a specified noxious stimulus in 50% of a test population) is
lowered by opioid drugs in most species studied. However, in horses most studies
reveal opioid drugs exert either a negligible or a MAC-increasing effect and consider-
able individual variation. For example, in an investigation of the MAC of halothane in 7
ponies47 acepromazine (0.05 mg/kg) reduced MAC by 36.9% (mean), whereas butor-
phanol (0.05 mg/kg) did not significantly change the mean group MAC value, although
it increased it in 3 ponies, decreased it in 1, and was without effect in the remaining
three. In another study48 the MAC of isoflurane was unaffected by low-dose morphine
(0.25 mg/kg) but was increased significantly by a higher dose (2.0 mg/kg). Again, the
effects were highly variable; MACwas reduced by 19% in one horse, and increased by
56% in another. No significant changes in MAC of halothane were identified before
and during the infusion of alfentanil (another opioid-3 agonist) given at 3 constant
rate infusions49 and the investigators concluded that plasma alfentanil concentrations
known to be effective in human beings and dogs did not induce an appreciable
change in halothane MAC in horses. In a fourth study50 butorphanol (0.022 mg/kg
and 0.044 mg/kg) decreased the MAC of halothane by 9% or 10%, depending on
the dose; however, this was not a statistically significant effect, and in 2 ponies,
MAC increased. These studies suggest that opioid drugs at certain doses stimulate
rather than depress CN activity in horses anesthetized with experimental techniques
and stimulated electrically.
The Benefits of Opioid Analgesics During Inhalation Anesthesia
Opioids are used in other species during inhalational anesthesia to reduce the require-
ment for volatile anesthetic, and thus preserve cardiopulmonary function. This situa-
tion may not apply in horses given their variable effect on MAC. However,
numerous studies show that intraoperative opioids given to horses undergoing
surgical procedures have negligible cardiopulmonary effect and improve the quality
of recovery (see later discussion), whereas at least 2 studies indicate an analgesic
and anesthetic-sparing effect. In one study51 involving 45 horses anesthetized for
arthroscopy with halothane, 31 horses received preoperative butorphanol (50 mg/kg
IV), whereas the remainder did not. The mean dose of vaporized halothane, the vapor-
izer dial setting, and the dose of dobutamine required to correct hypotension were
significantly lower in butorphanol recipients, whereas mean arterial blood pressure
was significantly higher. In a retrospective study of 82 surgical cases52 butorphanol
appeared to deepen isoflurane anesthesia without adversely affecting cardiovascular
variables. Furthermore, it appeared to obtund sympathetic stimulation arising from
surgery.
Opioid Analgesics in Experimental versus Clinical Inhalation Anesthesia
Studies showing MAC increase by opioid analgesics do not confirm the absence of an
analgesic effect12 during inhalation anesthesia for several reasons. First, electrical
stimulation is probably qualitatively different from surgical nocistimulation. Second,
even under general anesthesia, opioid stimulation may obfuscate more subtle signs
of antinociception. Extradural (rather than systemic) morphine (0.1 mg/kg) reduces
the MAC of halothane by 14% during pelvic limb stimulation.53 Third, MAC studies
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are performed on horses anesthetized with the drug being evaluated and no other,
which contrasts with a typical general anesthetic for animals undergoing surgery.
Fourth, the use of movement as an index of inadequate CN depression (ie, MAC)
has been challenged.54
Opioid Analgesics, Recovery from General Anesthesia, and Box-walking
Concerns have been raised12 that opioid-induced locomotor activity may adversely
affect recovery quality from anesthesia, whereas others have warned that opiates
may prolong recovery when given before animals have recovered consciousness.55
In support of these concerns, Steffey and colleagues48 described poor recoveries in
horses that had received 2.0 mg/kg morphine characterized by strong running or
galloping movements made while horses were still in lateral recumbency; preoperative
butorphanol (0.1 mg/kg IV) significantly prolonged recovery from a TIVA technique
used for colt castration.44
However, several studies have indicated that morphine does not impair recovery
quality after general anesthesia in clinical cases. One study, involving 25 horses under-
going minor orthopedic or soft-tissue surgery, found no differences in recovery quality
between horses receiving saline, butorphanol (50 mg/kg), or morphine (0.02 or 0.05
mg/kg).19 A retrospective study of 84 horses undergoing surgery found no significant
differences in the incidence of postoperative box-walking between horses receiving
(n 5 51) and not receiving morphine.56 Of the 2 horses that box-walked (one from
each group) that which had received morphine (120 mg/kg IV) was identified as
a habitual box-walker. In the United Kingdom, one study (n 5 8427) revealed that
1.1% of racehorses box-walk spontaneously and without anesthetic and/or surgical
provocation.57 Furthermore, Mircica and colleagues56 found recovery quality was
better in horses receiving morphine. Box-walking was similarly absent in a prospective
study of 22 horses undergoing elective surgical procedures in which 11 received
preinduction morphine (0.15 mg/kg) followed by its infusion (0.1 mg/kg/h) during halo-
thane anesthesia.58 In this study, morphine recipients recovered better than those not
receiving morphine, with quality differences increasing with the duration of anesthesia. In
a fourth study involving 38 thoroughbred horses undergoing upper airway surgery59 no
box-walking was observed in any horse but recovery quality was significantly better
in horses that received morphine (0.1 [n 5 13] and 0.2 [n 5 12] mg/kg). Meperidine
(2 mg/kg IM) injected at the end of 3 different anesthetic techniques in 128 horses
undergoing surgery and/or radiography did not affect recovery scores, nor the time
to achieve sternal recumbency or standing.60
The use of intraoperative opioids also reduces the need for postoperative analge-
sics. In one study61 analgesia was supplemented in 68 of 203 horses anesthetized
with halothane using butorphanol (up to 0.1 mg/kg) treated postoperatively with phen-
ylbutazone (4 mg/kg), flunixin (1 mg/kg), or carprofen (0.7 mg/kg). The need for addi-
tional postoperative analgesia was significantly reduced in horses receiving
butorphanol.
Reconciling Opioid-induced Locomotion Versus Improved Recovery Quality
One explanation for the absence of locomotor activity and improved recovery quality
in surgical cases compared with experimental horses is that the former receive seda-
tives (eg, a2 agonists), which may obscure any stimulant effects that high-dose
morphine or other opioids may exert, whereas drugs with antidopaminergic activity
(eg, acepromazine) may depress the neural processes promoting adverse reactions.62
Second, a2-agonist or phenothiazine drugs may potentiate the sedative and/or anal-
gesic properties of opioid analgesics. Third, opioid doses used in clinical studies
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are substantially less than those used in deliberate attempts to experimentally
produce side effects. Fourth, surgical pain may reveal the principal pharmacologic
quality of morphine (ie, analgesia) more reliably than laboratory nocistimulation (ie,
the drug performs better when real pain is present). These possibilities feature in
one study48 in which 6 pain-free horses anesthetized only with isoflurane had undesir-
able and dangerous recoveries after receiving high- (2.0 mg/kg) but not low- (0.25 mg/
kg) dose morphine. Clinical anecdotes attributing postoperative box-walking to opioid
analgesics may have described horses suffering from inadequate analgesia.
Increased locomotor activity is a common sign of pain in horses, particularly those
with gastrointestinal pain. Postoperative gastrointestinal pain is not uncommon in
horses deprived of analgesia. In one study63 horses not receiving phenylbutazone
after arthroscopy were more likely to show signs of postoperative abdominal discom-
fort than those receiving the drug. Such signs could have been attributed to opioid
analgesics, had they been given. In another study59 3 (of 12 horses) not receiving
morphine showed signs of postoperative abdominal discomfort, whereas 25 (of 25)
morphine recipients did not. In a study examining the postoperative effects of morphine56
one horse ran obsessively around the recovery box after standing, and could be halted
with difficulty only after 5 minutes. In this case, a misdiagnosis of opioid-induced loco-
motion could not be made because the horse had not received opioid analgesics. One
multicenter study examining the role of opioids in controlling colic pain43 graded
abdominal discomfort using signs that included sweating, exaggerated body move-
ment, heart and respiratory rates, continuous moving, stomping or pawing, weight-
shifting, and exaggerated responses to noise. The same study simultaneously used
sweating, excitation, cardiovascular or respiratory abnormalities, instability, and
abnormal reactions to sight, sound, or touch as indicators of opioid-induced side
effects. This study illustrates the potential to confuse signs of inadequate analgesia
and the side effects of an opioid analgesic. The ability of veterinary surgeons to distin-
guish signs of pain from excitatory opioid effects in horses should not be assumed.
The lack of consensus in the UK veterinary profession about whether a horse feels
pain after castration suggests that equine pain behaviors are not well recognized or
fully appreciated.3
DOES MORPHINE CAUSE POSTOPERATIVE COLIC?
The gastrointestinal effects of morphine that are held to predispose to postanesthetic
colic (PAC) have contributed to the unpopularity of opioid analgesics in horses.3
Opioid-induced dysfunction in chronically instrumented bowel loops in small numbers
of pain-free Equidae has been convincingly shown, although the clinical relevance of
such studies at times seems obscure. For example, morphine (0.5 and 1.0 mg/kg) and
fentanyl (10 or 50 mg, IV) initially stimulated, but then inhibited cecocolic electrical and
mechanical activity for up to 3 hours in 3 pain-free ponies, whereas naloxone (0.5 mg/
kg IV) elicited marked propulsive activity in the colonic segment.64 Other opioid drugs
behave similarly: meperidine (250 mg) and especially methadone (10 mg) decreased
the total electrical activity of a chronically instrumented bowel loop in 3 ponies.65
However, effects are often variable, and seem at odds with clinical observations. In
one study66 butorphanol (0.1 mg/kg) meperidine (1.0 mg/kg) and pentazocine (0.3
mg/kg) increased the duration of migrating myoelectric complexes (MMCs) in the
jejunum of 4 pain-free ponies, but although metoclopramide (30 mg/kg) had no effect
on MMCs it produced clinical signs of colic, whereas the opioid analgesics did not.
Morphine exerts a constipative effect in normal horses as in other species. In one
study67 morphine (0.5 mg/kg) given twice daily to 5 pain-free horses for 6 days
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decreased propulsive motility and moisture content in the gastrointestinal tract lumen.
The investigators concluded that the effects observed may predispose treated horses
to ileus and constipation although they did not reveal the medical indications for 6
days of morphine therapy in pain-free animals.
The volume of references to the adverse effects of m-agonists on equine gastroin-
testinal function contrasts with that on m-antagonist activity. Nevertheless, naloxone
(0.75 mg/kg IV) produced rapid onset diarrhea, restlessness, abdominal checking,
tachycardia, tachypnoea, and diaphoresis in 8 adult previously pain-free thorough-
breds, which the investigators concluded was an acute abdominal distress syndrome
similar to spasmodic colic.68 This finding confirms the complexity of equine gastroin-
testinal pharmacology and supports the possibility that inadequate analgesia may
have been responsible for signs previously attributed to morphine.
Nonopioid Causes of PAC in Horses
Other causes of gastrointestinal dysfunction may contribute to PAC in horses. Recent
changes inmanagement69–72 such as exercise, diet, and transport may increase risk in
hospitalized horses.73 Prolonged starvation (18 hours) has also been implicated.74
Sympathetic nervous stimulation as part of the stress response to anesthesia, surgery,
and nocistimulation decreases gastrointestinal motility in human beings75 and prob-
ably has similar effects in horses.76 Many drugs used to ameliorate the stress
response also depress gut motility, including a2-agonist drugs, which are almost
universally used for preanesthetic medication77,78 and nonsteroidal antiinflammatory
drugs (NSAIDs),79 which are commonly used for analgesic and antiendotoxic effects.
The combination of xylazine and ketamine (arguably one of the most popular means of
inducing anesthesia in horses) produced the longest period of hypomotility in one
myoelectrical study of equine intestinal activity.80 These findings challenge the justifi-
cation for implicating opioid drugs as a principal cause of postoperative colic, which is
unsupported by epidemiologic studies.
Postoperative Colic: Epidemiologic Studies
One study73 linked morphine with a 4-fold increase in risk of PAC after orthopedic
surgery compared with the use of butorphanol, or abstinence from opioid analgesia.
In this study, 14 horses develop colic after a total of 496 operations. However, despite
a population dose range of 0.08 to 0.3 mg/kg, 13 of the 14 cases that subsequently
developed colic received only 0.1 mg/kg. The study also failed to clarify the factors
determining morphine dose. It is therefore possible that severe orthopedic pain
contributed to postoperative gastrointestinal dysfunction in some of the horses that
developed colic. Another link between morphine and an increased prevalence of
PAC was identified in a different center,81 but the association disappeared when anal-
yses were stratified by procedure, indicating that the operation type was a greater risk
factor than the opioid analgesic. This study, which examined the anesthetic records of
553 horses (342 undergoing magnetic resonance imaging [MRI]; 211 having nonabdo-
minal [predominantly orthopedic] surgery), found 20 cases developed PAC,81 repre-
senting 7.1% of surgical and 1.5% of MRI cases. Increased risk was associated
with isoflurane, and the use of benzyl penicillin and/or ceftiofur for antibiosis. Factors
reducing risk were romifidine for preanesthetic medication, prolonged anesthesia, and
sedation within 2 days of general anesthesia. Perianesthetic morphine administration
was not associated with increased risk. A multicenter case-control study82 looking at
the prevalence of and risk factors associated with PAC in 861 horses undergoing non-
abdominal surgery found that the center involved and the operation type increased
risk, nonseptic orthopedic cases being at greatest risk. Preoperative food deprivation
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(horses that were not starved were more likely to develop colic) and opioid drugs were
confounding factors. In this study, 45 horses developed colic. Although the use of
opioid analgesics increased risk when compared with surgeries in which none were
used, there were no significant differences between butorphanol or morphine use.
The prevalence of PAC in those centers using butorphanol exclusively was the
same as those using only morphine. In one study60,61 of 38 thoroughbreds undergoing
upper airway surgery, the prevalence of decreased appetite for up to 4 postoperative
days in horses not receiving morphine (8 of 12) was similar with those receiving
morphine at 0.1 mg/kg (7 of 13) or 0.2 mg/kg (7 of 12). However, 3 (of 12) horses
not receiving morphine showed signs of postoperative discomfort consistent with
colic. No horses receiving morphine developed PAC. Butorphanol also seems to
confer benefit. Doses up to 100 mg/kg were used in a proportion of 203 horses under-
going surgery and randomly allocated to receive flunixin, carprofen, or phenylbuta-
zone. Signs of mild colic were observed in 18 horses but were unassociated with
use of butorphanol. Butophanol ensured a reduced requirement for postoperative
NSAID therapy.59 In another study56 there were no significant differences in the inci-
dence of postoperative gastrointestinal complications between horses receiving
(n 5 51) and not receiving (n 5 33) morphine at 100 to 170 mg/kg.
The literature indicates a multifactorial cause for PAC and an equivocal contribution
by morphine and other opioid analgesics. However, even unequivocal evidence for an
opioid-associated risk would have to be weighed against the better recoveries that
opioid analgesics promote. In 5 studies56,59,73,81,82 investigating opioid-induced
morbidities in a total of 2240 horses, PAC occurred in 100. None of these died directly
from postoperative colic and only 2 required surgical treatment. In contrast, fractures
in recovery, some of which are related to poor-quality recoveries, are the second
greatest cause of postoperative equine mortality.83
Opioid Analgesics in the Control of Gastrointestinal Pain
Some authorities, although acknowledging the efficacy of opioids as analgesics, have
condemned their use in equine colic because they cause excitation.21 Others have
suggested the ability of opioids to stimulate forceful contractions in an already dis-
tended bowel supports a relative contraindication for their use in colicky horses
with that condition.12 In 1946 Milks wrote, “Small doses [of morphine] are usually
sedative to the horse so that the drug is especially indicated in strong persistent
pain such as enteritis. It may often be extremely useful in spasmodic colic and
produces its action here by arresting the irregular and violent peristalsis which is the
cause of the pain.”84 Later support for the role of morphine in colic pain emerged in
a study that recorded gastrointestinal electrical potentials from 2 ponies that devel-
oped colic naturally.85 The investigators recommended the use of morphine because
“it provided concomitant antispasmodic action on the small bowels while stimulating
colonic activity.” This recommendation contrasts with the conclusion of a study78
examining the effects of xylazine (0.5 mg/kg) detomidine (12.5 mg/kg) and a xylazine
(0.5 mg/kg)-butorphanol (0.05 mg/kg) combination on equine duodenal motility that
concluded that “the profound suppressive effect of a routine dose of detomidine or
xylazine - butorphanol combination on equine duodenal motility must be considered
when using these agents for management of colic, especially when encouragement
of intestinal motility is desirable.”
In the clinical situation, the effective management of pain overrides theoretic
concerns with the effects of opioid analgesics on gastrointestinal function for at least
2 reasons: (1) it allows the safer diagnosis of surgical versus medical colic; and (2) it is
humane.
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CARDIOVASCULAR EFFECTS OF OPIOID DRUGS IN HORSES
The cardiovascular effects of opioid analgesics in horses seem to depend on the drug,
dose, administration route, and coadministered drugs, although the recipient’s level of
consciousness is important because cardiovascular hyperdynamism is often linked
with central nervous (CN) stimulation. Morphine can cause hypotension in human
beings by initiating histamine release with peripheral vasodilatation and tachycardia.
The likelihood of this is said to be greatest when high doses are given rapidly IV.
Morphine has caused urticarial lesions in horses, which may be linked to this finding,
although associated cardiovascular effects are unreported. This is not the case with
meperidine, which has caused severe reactions when given IV (1 mg/kg) in both
conscious and unconscious horses.86 In general, opioid drugs seem not to depress
cardiovascular variables in anesthetized horses to the same (modest) extent that
they do in other species,20 although all studies conducted in this area have involved
small numbers of pain-free horses or ponies.
Cardiovascular Effects of Opioid Analgesics in Conscious Horses
Intravenous morphine (0.12 mg/kg), meperidine (1.1 mg/kg), oxymorphone (0.03 mg/
kg), methadone (0.12 mg/kg), and pentazocine (0.9 mg/kg) caused similar levels of
cardiovascular stimulation87 linked with dysphoria and euphoria. Heart rate (HR)
increased after injection but returned to baseline within 30 minutes. Systolic (SAP),
mean (MAP), and diastolic (DAP) arterial pressures increased significantly although
transiently. In another study21 morphine (0.66 mg/kg IM) caused excitation and
increased all cardiovascular variables for at least 4 hours. Buprenorphine (10 mg/kg
IV) also stimulated 6 pain-free horses, causing a sustained (120- minute) increase in
HR, SAP, MAP, and DAP and cardiac index.27 However, in another buprenorphine
study several effects did not coincide with CN system activity: 3 mg/kg IV caused
a marked and lasting hypertension without a corresponding HR increase. In one horse
that became sedated DAP, but not SAP, increased without a concomitant increase in
HR.26
Cardiovascular and CN stimulation are variably linked in horses receiving butorpha-
nol. Intravenous doses of 0.1, 0.2, and 0.4 mg/kg caused predominantly excitatory
signs yet did not significantly affect HR, MAP, or DAP.88 In another study23 IV butor-
phanol (0.1–0.13 mg/kg) caused gross behavioral disturbances although the HR was
unaltered in 4 of 7 animals. Although these studies suggest that the depressant effect
of butorphanol on HR overcomes the chronotropy of CN stimulation, another study21
found 0.22 mg/kg increased HR. Furthermore, neither HR nor MAP changed from pre-
injection values when butorphanol (0.05 mg/kg) was injected IV in horses anesthetized
with halothane undergoing minor orthopedic or soft-tissue surgery.19
Cardiovascular Effects of Opioid Analgesics with a2 Agonists
The cardiovascular effects of opioid/a2 agonist combinations are unpredictable
because the latter have complex time- and dose-dependent effects, whereas their
sedative properties ameliorate any opioid-induced CN stimulation in nonpainful
horses. Most studies indicate the hemodynamic effects of a2 agonists prevail over
those of opioid analgesics. For example, in one study, butorphanol (50 mg/kg, IV)
added to one of 2 romifidine doses (40 and 80 mg/kg, IV) had no effect on HR and
MAP compared with those of romifidine alone.40 In another study,20 2 doses of
morphine (0.12 and 0.66 mg/kg) given to horses presedated with xylazine (0.66 mg/
kg) caused similar significant decreases in cardiac output (Qt) and increases in central
venous pressure, SAP, MAP, DAP, and pulmonary arterial pressure.
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Detomidine (10 mg/kg) seems to ameliorate opioid-induced cardiovascular effects
less than xylazine and romifidine.9 When morphine (0.1 mg/kg), methadone (0.1 mg/
kg), meperidine (1.0 mg/kg), or butorphanol (50 mg/kg) were administered IV to
pain-free ponies and a thoroughbred sedated 6 minutes earlier with detomidine (10
mg/kg), marked tachycardia and hypertension followed morphine and meperidine
injection, although cardiovascular changes were minimal within 5 minutes. This finding
was not associated with excitation except in one pony whose HR rose to 70 beats per
minute and MAP to 200 mm Hg. Despite preexisting sedation, meperidine caused
marked excitation in one pony and increased HR to 100 beats per minute and MAP
to 215 mm Hg.
Cardiovascular Effects of Opioid Analgesics with Inhalant Anesthetics
Opioids seem to have little, if any, cardiovascular effects in anesthetized horses under-
going surgery. Neither HR nor MAP changed when intravenous morphine (20 and 50
mg/kg) or butorphanol (0.05 mg/kg) were given to horses anesthetized with halothane
undergoing minor orthopedic or soft-tissue surgery.19 The incidence of bradycardia,
tachycardia, hypertension, and hypotension was similar in 84 horses anesthetized
with halothane irrespective of whether morphine (100–170 mg/kg) was given or not
(n 5 33).56 In another study89 19 of 38 horses anesthetized with halothane received
preoperative morphine (0.15 mg/kg IV) followed by infusion (0.1 mg/kg/h). There
were no significant differences in the MAP or HR of these animals compared with
those receiving the same anesthetic without morphine. Butorphanol also exerted little
measurable effect in horses anesthetized with isoflurane.52 A retrospective evaluation
of anesthetic records from 76 horses anesthetized for various operations revealed that
butorphanol did not affect SAP, MAP, DAP, or HR, causing the investigators to
conclude that butorphanol can be administered to horses during isoflurane anesthesia
without adverse cardiovascular effects.
Pharmacologic relationships do not seem to allow the prediction of the effect of
a drug. In one study of horses anesthetized with halothane not undergoing surgery50
infused alfentanil caused dose-dependent increases in blood pressure, although HR
did not change. In contrast, the related phenylpiperidine derivative sufentanil (1 and
2 mg/kg IV) transiently reduced MAP and HR in 6 different animals similarly
anesthetized.90
It is possible that surgical nocistimulation during inhalation anesthesia offsets any
opioid-induced cardiovascular depression, whereas general anesthesia obtunds sym-
pathoadrenal responses arising from opioid-induced CN stimulation.
RESPIRATORY EFFECTS OF OPIOID DRUGS IN HORSES
The respiratory effects of morphine and other opioid drugs in horses also seem to
depend on whether recipients are conscious and excitable, or unconscious,87
although this is not always predictable.
Respiratory Effects of Opioid Analgesics in Conscious Horses
In one study, butorphanol (0.1, 0.2, and 0.4 mg/kg IV) caused excitatory signs but did
not significantly affect respiratory rate (fr), arterial blood gas values, or arterial pH
(pHa).23 In contrast, buprenorphine (10 mg/kg IV) caused CN stimulation and increased
fr although the arterial partial pressure of oxygen (PaO2) and carbon dioxide (PaCO2)
and hemoglobin saturation (as determined by pulse oximetry [SpO2]) were
unchanged.27 Changes are usually minor and drug dependent. In a comparison of
morphine (0.12 mg/kg IV), meperidine (1.1 mg/kg IV), oxymorphone (0.03 mg/kg IV),
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methadone (0.12 mg/kg IV), and pentazocine (0.9 mg/kg IV)87 fr was unchanged or
initially increased and then decreased minimally. Although PaCO2 decreased slightly,
arterial and venous O2 tensions and pH were unchanged. The fr was changed least
by morphine, meperidine, and oxymorphone and most by methadone. In general,
changes were linked with dysphoria and euphoria. In another study21 comparing
butorphanol (0.22 mg/kg), flunixin (2.2 mg/kg), levorphanol (0.033 mg/kg), and
morphine (0.66 mg/kg), butorphanol, flunixin, and levorphanol produced no effect
on fr or blood-gas values, whereas morphine increased fr for 4 hours without affecting
blood gas values. One study26 concluded that the modest respiratory effects
(increased fr and minute expiratory ventilation with reduced tidal volume) of buprenor-
phine (3, 5, and 10 mg/kg IV) were not dose related, nor linked with CN excitation.
Respiratory Effects of Opioid Analgesics with a2 Agonists
a2 agonists seem to modestly potentiate the respiratory depressant effects of some,
but not all, opioid drugs. Detomidine (10 mg/kg) given alone or followed with morphine
(0.1 mg/kg), methadone (0.1 mg/kg), meperidine (1.0 mg/kg), or butorphanol (50 mg/
kg) was studied in 3 ponies and a thoroughbred. Morphine caused modest falls in
PaO2 and rises in PaCO2, whereas meperidine increased only PaCO2.
9 The effect may
depend on the a2 agonist involved: butorphanol (50 mg/kg IV) had no effect on PaO2
and pHa, but significantly increased PaCO2 for 20 minutes when added to romifidine
(40 and 80 mg/kg, IV).40
The dose of opioid involved seems to be unimportant. Two doses of morphine (0.12
and 0.66 mg/kg) given to 9 horses sedated with xylazine (0.66 mg/kg) caused similar
and significant decreases in fr whereas PaCO2, PaO2, and pHa remained unchanged.
20
Respiratory Effects of Opioid Analgesics with Inhalant Anesthetics
Neither low morphine doses (20 and 50 mg/kg) nor butorphanol (0.05 mg/kg) caused
significant changes from preinjection values for fr, PaCO2, PaO2 and airway occlusion
pressure in horses anesthetized with halothane.19 In another study of horses anesthe-
tized with halothane undergoing elective surgery, the preoperative injection of
morphine (0.15 mg/kg IV) followed by infusion (0.1 mg/kg/h) did not cause significant
differences in PaO2 or PaCO2 when compared with horses from which morphine was
withheld.89
These data do not support the widely held view9,24 that high doses of intraoperative
opioids depress ventilation in unconscious horses, a view to which this author
subscribes.
MORPHINE AND PULMONARY EDEMA
Despite its mild cardiopulmonary effects, morphine has been implicated in 2 cases of
postoperative pulmonary edema.91 Although the investigators identified numerous
risk factors92 in both cases, they concluded that fluid overload was worsened by
a “morphine-induced reduction in urine production,” and by “potential morphine-
induced changes in pulmonary permeability.” This reveals the most useful role of
morphine in equine anesthesia: to assume responsibility for any untoward periopera-
tive event.
OPIOID ANALGESICS IN HORSES: RECOMMENDATIONS
Recommended doses of opioid analgesics in horses vary widely (Table 2) because the
effective dose depends on numerous factors. Dosing should follow 4 general rules: (1)
the more severe the pain (or the greater the surgical insult), the greater the dose of
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opioid analgesic required, and the lower the risk of excitatory side effects; (2) in pain-
free horses, giving appropriate doses of a2 agonists matched for duration of action
eliminates the risk of excitation; acepromazine reduces, but does not eliminate, risk;
(3) although opioid analgesics are described in terms of duration of action, they should
be given to effect (ie, when the desired level of analgesia has waned below acceptable
levels), and not by the clock; and (4) clinical signs of underdose (ie, pain) may mimic
signs of overdosage.
NEW TECHNIQUES FOR PERIOPERATIVE OPIOID ANALGESIA
Extradural Opioid Analgesia
Extradural morphine injection consistently suppresses responses to experimental and
clinical nocistimulation in horses without causing sensory, sympathetic nervous, or
motor blockade. This subject is discussed elsewhere.
Opioid Analgesics and Intraarticular Analgesia
Opioid receptors have been identified on peripheral terminals of sensory nerves,
whereas opioid peptide ligands (principally b-endorphin and met-encephalin) have
been discovered in immune cells from inflamed synovial tissue of human patients
undergoing arthroscopic knee surgery.95 The identification of opioid receptors in the
equine synovia96 has stimulated interest in producing intraarticular (IA) opioid anal-
gesia in horses.
Initial studies showed an absence of tissue irritancy or systemic effects after IA
morphine. No evidence of adverse local reactions or systemic effects were seen after
IA morphine sulfate (1 mg) or buprenorphine hydrochloride (300 mg) injection into the
middle carpal joints of 5 ponies. However, the vehicles of each drug were not
detailed.97 The disposition and local effects (15 mg in 5 mL saline) of morphine
were also studied after injection into the tarsocrural joint of normal ponies.98 Morphine
remained detectable in synovial fluid 24 hours after injection, although systemic levels
were unmeasureable after 6 hours. No adverse systemic effects were seen. The injec-
tion contained 0.1% w/v sodium metabisulfite but morphine did not irritate the joint
any more than saline.
Table 2
Recommended doses of opioid analgesics in horses
Analgesia Preoperative Intraoperative Postoperative
Morphine 0.05–0.1 mg/kg
IV or IMa 24,93
0.1–0.3 mg/kg IVb
0.15 mg/kg58,59 0.1 mg/kg/h58,59 0.1–0.2 mg/kgb
Meperidine 0.3–0.6 mg/kg IV93
1–2 mg/kg IM only24
2 mg/kg IM62,63
Methadone 0.05–0.1 mg/kg93
0.1 mg/kg IV or IM24
Butorphanol 0.01–0.02 mg/kg93
0.05–0.1 mg/kg24
13 mg/kg/h94,b
Buprenorphine 10–20 mg/kg IV93
60 mg/kg IV or IM24
a All doses intravenous unless stated otherwise.
b Author’s preference.
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A later study99 compared the analgesic efficacy of IA and intravenous morphine
(0.05/mg both routes) in horses with experimentally induced radiocarpal synovitis.
As might be expected from the predictable differences in effector site drug concentra-
tion, IA morphine resulted in significantly less lameness than intravenous morphine,
although overall pain scores did not differ between treatments. The results indicate
the potential usefulness of IA morphine after arthroscopic surgery, although further
studies in clinical cases are needed. The analgesic effects of IA morphine (40 mg)
were compared with the local anesthetic ropivacaine (40 mg) and a ropivacaine (20
mg)-morphine (200 mg) mixture injected intraarticularly in 12 horses with experimen-
tally induced radiocarpal synovitis.100 Ropivacaine produced approximately 3 hours of
analgesia after a rapid onset, whereas morphine had a slower onset but a greater anal-
gesic effect of longer duration (>24 hours). The combination combined the advantages
of both drugs.
Transdermal Fentanyl Analgesia
The fentanyl transdermal therapeutic system or patches has become popular in small
animals and has recently been studied in horses. Plasma fentanyl concentration
during transdermal administration depends on the properties of the skin and so may
vary with the application site of the patches. An in vitro101 study of equine skin from
thoracic, inguinal, and dorsal metacarpal areas revealed similar values for fentanyl
flux (over 48 hours) for thoracic and inguinal skin, which were greater than those
from the dorsal metacarpus. Fentanyl penetration through inguinal skin was signifi-
cantly slower compared with the other 2 sites. Two 100-mg/h fentanyl patches applied
to the lateral necks of 3 horses weighing 352 to 459 kg102 resulted in rapid absorption,
with plasma fentanyl levels exceeding 2 ng/mL after 4 hours. Peak plasma concentra-
tions (3.85 ng/mL) occurred at 6.7 hours, after which levels declined over 48 hours but
remained greater than 1 ng/mL (which is held to represent an analgesic concentration
in other species) for 54 hours. Plasma drug levels decreased rapidly after patch
removal and no adverse behavioral responses were reported. In another study103
3 10-mg patches (equivalent to 60–67 mg/kg) were applied to the middorsal thorax
and resulted, after a 2-hour lag period, in a rapid increase in plasma fentanyl concen-
tration, which was a maximum at 12 hours and declined thereafter in a near-linear
fashion. However, there was much individual variation. In 2 horses, plasma concentra-
tions failed to reach 1 ng/mL. In the remaining four it was greater than 1 ng/mL for at
least 40 hours and longer than 72 hours in two of these. No adverse effects attributable
to fentanyl were observed, indicating that the dose tested was safe in healthy adult
horses. However, it failed to achieve plasma fentanyl concentrations generally consid-
ered to be analgesic in about one-third of horses. The clinical efficacy of transdermal
fentanyl was investigated in 9 horses whose pain was unresponsive to phenylbuta-
zone (n 5 3) or flunixin (n 5 6) and which subsequently received between 39 and
110 mg/kg of transdermal fentanyl.104 One 10-mg patch was applied per 150 kg of
body mass to the lateral cervical and/or lateral or medial proximal antebrachial
area. After administration, mean time to serum fentanyl concentrations greater than
1 ng/mL was 14 hours. Serum fentanyl concentrations 1 ng/mL or greater were main-
tained in all but one horse for at least 18 hours. No adverse effects were observed.
Pain scores were significantly decreased after fentanyl and NSAID administration
but improvement was minimal in horses with orthopedic disease, and lameness
scores did not change in the 3 horses with septic physitis or osteomyelitis. That trans-
dermal fentanyl is less effective at relieving orthopedic pain compared with soft-tissue
pain has been observed elsewhere.105
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SUMMARY
A questionnaire-based study of UK equine veterinarians’ attitudes to analgesics
(which confused the terms potency with efficacy) revealed the most important deter-
minant of choice was the perceived potency of a drug.3 Fears of adverse gastrointes-
tinal and locomotor effects were also important. These fears have been generated
by studies that lack external validity, having been conducted on small numbers of
pain-free horses or ponies, exposed to artificial, rather than surgical or traumatic,
nocistimulation and not receiving the range of drugs that would be the case in the peri-
operative or trauma setting. Similarities between equine pain behaviors and opioid
side effects make it possible that some adverse reactions attributed to drugs were
signs of inadequate analgesia. Despite increasing evidence of their clinical usefulness,
unenlightened assertions concerning opioid analgesics continue to be made. The
statement “Opioids are not widely used in horses because they can cause CN system
excitation, sympathetic stimulation, and can stimulate locomotion” was recently used
to justify an experimental study of the analgesic activity of tramadol in pain-free
horses.106 To show that the margin between the analgesic and stimulant effects of
opioid analgesics in horses is probably much broader than hitherto proposed requires
(1) an improved ability to recognize equine pain; (2) a precise and valid equine pain
scoring system; (3) the use of effective, not excessive, opioid doses; (4) a large number
of animals with actual, rather than experimentally induced, pain.
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